Delpharm acquires Sandoz sterile injectable production facility

1 minute read
01 March 2022

On March 1, 2022, Delpharm Industrie ("Delpharm") announced that it had acquired the Sandoz Canada manufacturing plant located in Boucherville, Québec, from Novartis. This plant is the largest sterile injectable production facility in Canada and provides medicines to the Canadian and US healthcare systems, mostly hospitals. 

Delpharm, based in France, owns eighteen pharmaceutical production sites globally and is one of the top five contract development and manufacturing companies (CDMO) in the world. This latest acquisition represents the second production site in Canada for Delpharm.
Gowling WLG advised Delpharm in this acquisition with a team led by Marc Tremblay, and that included Stefan Nasswetter (corporate/M&A), Ian Macdonald and Elad Gafni (competition), Laura Gheorghiu (tax), Evan Atwood (regulatory), Pierre-André Hamel (real estate), Luc Deshaies (employment) and Nicolas Dubé (environmental).

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.